◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › H › HROW

Harrow Health Inc (HROW) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-16

Harrow Health Inc (HROW) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Nashville, United States with about 373 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, HROW reported $272M in revenue and ($5M) in net income.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.

Interactive charts & full statements → Open the HROW valuation workbench →

HROW Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$276M	$272M	$200M	$130M	$89M	$72M	$49M	$51M	$41M	$27M	$20M	$10M	$2M	$0M	$0M	—	—	—	—	—	—
Gross Profit	$202M	$204M	$150M	$91M	$63M	$54M	$34M	$34M	$25M	$13M	$10M	$5M	$1M	$0M	$0M	—	—	—	—	—	—
Gross Margin %	73.3%	75.0%	75.3%	69.5%	71.4%	74.9%	70.4%	67.3%	60.1%	49.6%	50.7%	46.4%	34.2%	100.0%	100.0%	—	—	—	—	—	—
Operating Income (EBIT)	$6M	$39M	$9M	$0M	$2M	$2M	$0M	($5M)	($5M)	($12M)	($16M)	($15M)	($10M)	($8M)	($4M)	($1M)	($3M)	($5M)	($4M)	($3M)	($1M)
Operating Margin %	2.1%	14.2%	4.4%	0.3%	2.2%	2.2%	0.8%	-9.4%	-12.6%	-45.4%	-79.6%	-152.6%	-611.3%	-76868.8%	-4179.0%	—	—	—	—	—	—
Net Income	($37M)	($5M)	($17M)	($24M)	($14M)	($18M)	($3M)	$0M	$15M	($12M)	($19M)	($16M)	($10M)	($8M)	($5M)	($1M)	($3M)	($5M)	($3M)	($4M)	($1M)
Net Margin %	-13.5%	-1.9%	-8.8%	-18.8%	-15.9%	-24.9%	-6.9%	0.3%	35.4%	-44.8%	-95.7%	-163.6%	-609.5%	-76431.2%	-5384.0%	—	—	—	—	—	—
EBITDA	$4M	$41M	$22M	$12M	($4M)	$5M	$3M	$2M	($3M)	($10M)	($14M)	($14M)	($10M)	($8M)	($5M)	($1M)	($3M)	($5M)	($4M)	($3M)	($1M)
Earnings Per Share (EPS)	$-1.00	$-0.14	$-0.49	$-0.75	$-0.51	$-0.67	$-0.13	$0.01	$0.61	$-0.60	$-1.50	$-1.66	$-1.11	$-0.88	$-1.20	$-2.40	$-6.41	$-11.67	$-8.92	$-19.37	$-6.44
Shares Outstanding (M)	37M	37M	36M	33M	27M	27M	26M	26M	24M	20M	13M	10M	9M	9M	4M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HROW Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$71M	$44M	$89M	$72M	$64M	$48M	$67M	$49M
Gross Profit	$50M	$27M	$71M	$54M	$48M	$32M	$53M	$37M
Gross Margin %	71.3%	61.2%	79.3%	75.3%	74.5%	67.5%	78.8%	75.6%
Operating Income (EBIT)	($11M)	($22M)	$24M	$15M	$11M	($11M)	$13M	$1M
Operating Margin %	-15.6%	-50.0%	27.0%	20.6%	17.9%	-23.5%	19.3%	2.7%
Net Income	($17M)	($28M)	$7M	$1M	$5M	($18M)	$7M	($4M)
Net Margin %	-24.4%	-62.4%	7.4%	1.4%	7.8%	-37.2%	10.1%	-8.6%
EBITDA	($11M)	($16M)	$20M	$12M	$16M	($7M)	$18M	$4M
Earnings Per Share (EPS)	$-0.46	$-0.74	$0.18	$0.03	$0.13	$-0.50	$0.19	$-0.12
Shares Outstanding (M)	37M	37M	37M	39M	39M	36M	36M	36M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HROW Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$6M	$44M	($22M)	$4M	$2M	$5M	($1M)	$1M	$1M	($9M)	($11M)	($11M)	($7M)	($4M)	($2M)	$0M	($2M)	($4M)	($3M)	($2M)	$0M
Capital Expenditures (CapEx)	$1M	$1M	$39M	$153M	$8M	$29M	$1M	$2M	$2M	$1M	$7M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$5M	$43M	($61M)	($149M)	($6M)	($23M)	($2M)	($1M)	($2M)	($10M)	($18M)	($12M)	($7M)	($4M)	($2M)	$0M	($2M)	($4M)	($3M)	($2M)	$0M
FCF Margin %	1.9%	15.7%	-30.5%	-114.2%	-6.9%	-32.3%	-4.3%	-1.7%	-3.7%	-36.9%	-92.0%	-126.8%	-435.5%	-44589.5%	-1916.3%	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$1M	$0M	$0M	$0M	$0M	—	$4M	$8M	$0M	—	$0M	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HROW Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($10M)	($9M)	$8M	$17M	($1M)	$20M	($18M)	$3M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$38M	$1M
Free Cash Flow (FCF)	($10M)	($9M)	$8M	$16M	($1M)	$19M	($55M)	$2M
FCF Margin %	-14.1%	-20.8%	9.1%	22.8%	-1.5%	40.7%	-82.8%	4.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HROW Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$417M	$399M	$389M	$312M	$157M	$98M	$57M	$59M	$49M	$24M	$27M	$14M	$10M	$16M	$11M	$0M	$0M	$2M	$5M	$4M	$0M
Cash & Cash Equivalents	$84M	$73M	$47M	$74M	$96M	$42M	$4M	$5M	$7M	$4M	$9M	$3M	$8M	$16M	$10M	$0M	$0M	$2M	$5M	$4M	$0M
Total Liabilities	$402M	$347M	$320M	$242M	$130M	$87M	$31M	$32M	$25M	$21M	$21M	$16M	$2M	$1M	$1M	$2M	$1M	$1M	$1M	$1M	$0M
Total Debt (Short + Long-Term)	$293M	$244M	$220M	$184M	$105M	$72M	$17M	$15M	$16M	$15M	$13M	$8M	$0M	$0M	$0M	$1M	$1M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$15M	$52M	$70M	$70M	$27M	$11M	$27M	$28M	$25M	$3M	$6M	($1M)	$8M	$15M	$10M	($2M)	($1M)	$1M	$5M	$3M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HROW viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

ANIP · ANI Pharmaceuticals Inc — $2 billion
ETON · Eton Pharmaceuticals Inc — $2 billion
XERS · Xeris Pharmaceuticals Inc — $1 billion
PAHC · Phibro Animal Health Corporation — $1 billion
CRON · Cronos Group Inc — $1 billion
PCRX · Pacira BioSciences, Inc. — $984 million
GLAS · Glass House Brands Inc. — $800 million
TAK · Takeda Pharmaceutical Co Ltd ADR — $60 billion

← HRON All “H” companies HRPK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.